Literature DB >> 8901839

Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study.

F Cambien1, S Ricard, A Troesch, C Mallet, L Générénaz, A Evans, D Arveiler, G Luc, J B Ruidavets, O Poirier.   

Abstract

Transforming growth factor-beta 1 (TGF-beta 1) plays an important role in the modulation of cellular growth and differentiation and the production and degradation of the extracellular matrix. A number of experimental results suggest that TGF-beta 1 may be involved in cardiovascular physiopathology. In the present study, we assessed whether the TGF-beta 1 gene is a candidate gene for coronary heart disease or hypertension. We screened the coding region and 2181 bp upstream of the TGF-beta gene for polymorphisms and identified seven polymorphisms: 3 in the upstream region of the gene at positions -988, -800, and -509 from the first transcribed nucleotide; 1 in a nontranslated region at position +72; 2 in the signal peptide sequence Leu10-->Pro, Arg25-->Pro; and 1 in the region of the gene coding for the precursor part of the protein not present in the active form, Thr263-->Ile. We analyzed these TGF-beta 1 polymorphisms in 563 patients with myocardial infarction and 629 control subjects from four regions in Northern Ireland and France. The Pro25 allele was more frequent in patients than in control subjects in Belfast (P < .01) and Strasbourg (P < .05). The TGF-beta 1 polymorphisms were not associated with the degree of angiographically assessed coronary artery disease in patients. The presence of a Pro25 allele was associated with a lower systolic pressure in the four control groups (P < .002), and a history of hypertension was significantly less frequent in homozygotes or heterozygotes for Pro25 than in hormozygotes for Arg25 (odds ratio, 0.43, 95% confidence interval, 0.19 to 0.92; P < .03). Since the Pro25 allele was associated with an increased risk of myocardial infarction and a reduced risk of hypertension, we favor a cautious interpretation of these apparently inconsistent results. Other studies will need to verify whether these associations are real.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901839     DOI: 10.1161/01.hyp.28.5.881

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  81 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies.

Authors:  F Andreotti; I Porto; F Crea; A Maseri
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

Review 3.  Cardiac genes and gene databases for cardiovascular disease genetics.

Authors:  K T Tan; A Dempsey; C C Liew
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

4.  A profibrotic polymorphism (of TGFbeta1) in systemic sclerosis.

Authors:  J P Pandey; E C LeRoy
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

5.  The genetics of response to estrogen treatment.

Authors:  Bente L Langdahl
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

6.  Transforming growth factor-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Masatomo Miura; Yudai Hinai; Hajime Saito; Manabu Ito; Takashi Ono; Hiroshi Toda; Satoru Motoyama; Jun-ichi Ogawa
Journal:  Tumour Biol       Date:  2010-05-27

7.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

8.  A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER(+), PR(+), ER(+)PR(+) and HER2(-) expression in women.

Authors:  Mei Zhang; Ling-Ling Guo; Zhongqin Cheng; Reng-Yun Liu; Yufeng Lu; Qian Qian; Zhe Lei; Hong-Tao Zhang
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

9.  Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas.

Authors:  Olivera Tarabar; Bojana Cikota-Aleksić; Ljiljana Tukić; Nenad Milanović; Aleksandar Aleksić; Zvonko Magić
Journal:  Int J Clin Oncol       Date:  2013-03-27       Impact factor: 3.402

10.  Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia.

Authors:  Barbara S Saltzman; Jennifer F Yamamoto; Robert Decker; Lance Yokochi; Andre G Theriault; Thomas M Vogt; Loïc Le Marchand
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.